Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Gene Ther. 2012 Jun 7;20(3):318–327. doi: 10.1038/gt.2012.42

Figure 1.

Figure 1

In vitro effects of VEGF neutralization on adenovirus replication. (A) Flow cytometry analysis of U251 glioma cell line for expression of surface receptor CAR, αvβ3, αvβ5 and CD138. The percentages of positive cells for the respective receptors are shown in bar diagrams, below the flow cytometry histograms. (B and C) CRAd-S-pk7 replication in U251 glioma treated with VEGF-Ab was quantified via quantitative real-time PCR for E1A (B) or adenovirus progeny titer (C). (D) Toxicity of CRAd-S-pk7 in combination with VEGF-Ab in U251 glioma cells five days after infection (ns: not significant; *p<0.05; *** p<0.001).